The anticancer effects of HDAC inhibitors require the immune system
Alison C West, Mark J Smyth, Ricky W Johnstone
ONCOIMMUNOLOGY | LANDES BIOSCIENCE | Published : 2014
Histone deacetylase inhibitors (HDACis) are known to exert immunomodulatory effects. We have recently demonstrated that the therapeutic efficacy of HDACis against aggressive B-cell lymphoma and colon carcinoma relies on a functional immune system, in particular on the production of interferon γ (IFNγ). Our findings provide a rationale for the combination of HDACis with immunotherapeutic agents in the clinic.